标题
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
作者
关键词
-
出版物
Pharmaceuticals
Volume 13, Issue 12, Pages 418
出版商
MDPI AG
发表日期
2020-11-24
DOI
10.3390/ph13120418
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
- (2020) Scott F. Schoninger et al. MOLECULAR CANCER THERAPEUTICS
- Requirement for epithelial p38α in KRAS-driven lung tumor progression
- (2020) Jessica Vitos-Faleato et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies
- (2020) Marina N. Sharifi et al. CANCER
- The role of CDK6 in cancer
- (2020) Sofie Nebenfuehr et al. INTERNATIONAL JOURNAL OF CANCER
- CDK6 Inhibition: A Novel Approach in AML Management
- (2020) Iris Z. Uras et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments
- (2020) Angelina Pranteda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma
- (2020) Ziyi Li et al. GENOMICS PROTEOMICS & BIOINFORMATICS
- A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
- (2020) Jonathan W. Goldman et al. Frontiers in Oncology
- Cdk6 coordinates Jak2V617F mutant MPN via NFκB and apoptotic networks
- (2019) Iris Z. Uras et al. BLOOD
- CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
- (2019) Kai Zhang et al. CANCER LETTERS
- Dual inhibition of MEK and p38 impairs tumor growth in KRAS‑mutated non‑small cell lung cancer
- (2019) Noriaki Sunaga et al. Oncology Letters
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
- (2019) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical characterization of SHR 6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
- (2019) Fei Long et al. CANCER SCIENCE
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- MONALEESA clinical program: a review of ribociclib use in different clinical settings
- (2019) Denise A Yardley Future Oncology
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
- (2019) J M Weiss et al. ANNALS OF ONCOLOGY
- p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
- (2019) Keelan Z. Guiley et al. SCIENCE
- Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
- (2018) Begoña Cánovas et al. CANCER CELL
- MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
- (2018) Renée de Leeuw et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
- (2018) Priyank Patel et al. MOLECULAR CANCER RESEARCH
- CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
- (2018) Florian Bellutti et al. Cancer Discovery
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
- (2018) Shom Goel et al. TRENDS IN CELL BIOLOGY
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
- (2017) Xin Li et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
- (2017) Jiayuan Wang et al. Journal of Translational Medicine
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
- (2017) S-H Chen et al. ONCOGENE
- Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
- (2017) H S Kim et al. ONCOGENE
- Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
- (2017) Shenghui He et al. Science Translational Medicine
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).
- (2017) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
- (2017) Mark Merchant et al. PLoS One
- Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
- (2016) I. Z. Uras et al. BLOOD
- Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
- (2016) Zhen Li et al. CANCER LETTERS
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
- (2016) Lori S. Hart et al. CLINICAL CANCER RESEARCH
- Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
- (2016) Guowei Gu et al. CURRENT OPINION IN PHARMACOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
- (2016) J. E. Bisi et al. MOLECULAR CANCER THERAPEUTICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
- (2016) Michael S. Lee et al. Oncotarget
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib
- (2016) Mark A. Dickson et al. JAMA Oncology
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
- (2015) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Stress Kinase p38 as a Target for Cancer Therapy
- (2015) A. Igea et al. CANCER RESEARCH
- Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
- (2015) Veronika Malínková et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
- (2015) Thomas F Eleveld et al. NATURE GENETICS
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
- (2015) A-S Tigan et al. ONCOGENE
- The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
- (2015) Rachel Ramsdale et al. Science Signaling
- The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
- (2015) Rachel Ramsdale et al. Science Signaling
- c-JUN prevents methylation of p16INK4a (and Cdk6): the villain turned bodyguard
- (2015) Karoline Kollmann et al. Oncotarget
- CDK6 and p16INK4a in lymphoid malignancies
- (2015) Karoline Kollmann et al. Oncotarget
- Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
- (2014) T. Placke et al. BLOOD
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3
- (2014) Zhihong Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
- (2014) K. Keegan et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK
- (2013) Lorena Pereira et al. EMBO Molecular Medicine
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Targeting cell cycle and hormone receptor pathways in cancer
- (2013) C E S Comstock et al. ONCOGENE
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
- (2012) Jeffry L. Dean et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
- (2010) S. Paillas et al. CANCER RESEARCH
- Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
- (2010) J L Dean et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now